More than 170 million women worldwide are affected by a condition previously known as polycystic ovary syndrome, which has been officially renamed following a campaign led by patients and health advocates. The new name, SOMP (Síndrome dos Ovários Multicísticos Poliendócrinos), replaces the term “polycystic ovary syndrome” (PCOS) to better reflect the condition’s characteristics and reduce stigma, according to health officials.
A Shift in Terminology
The reclassification was announced after a multi-year effort by patient groups and medical experts to address concerns that the previous name was misleading. The term “polycystic” historically emphasized the presence of cysts on the ovaries, but recent research indicates that not all individuals with the condition exhibit this feature. The updated name highlights the condition’s hormonal and metabolic aspects, which are central to its impact on patients.
“The old name didn’t capture the full scope of what this condition entails,” said a representative from a patient advocacy organization. “This change is about accuracy and ensuring patients feel understood.”
Medical Review Sparks Debate
A recent review of clinical guidelines reevaluated the diagnostic criteria for the condition, emphasizing the role of insulin resistance, irregular menstrual cycles, and hormonal imbalances. Researchers noted that the previous focus on ovarian cysts may have led to underdiagnosis in some cases, particularly among individuals whose symptoms did not align with the traditional definition.
Health professionals involved in the review stated that the updated terminology aims to improve communication between patients and clinicians. “This is not just a semantic shift—it reflects a deeper understanding of the condition’s complexity,” said one endocrinologist.
Patient Advocacy Drives Change
The name change followed a grassroots campaign by women who described years of frustration with misdiagnosis and inadequate treatment. Many reported feeling dismissed by healthcare providers who focused on the term “polycystic” rather than the broader symptoms they experienced. The campaign gained momentum through social media and patient forums, amplifying calls for a more inclusive and accurate label.
“For so long, we were told our symptoms were ‘normal’ or ‘not serious,’” said a patient who participated in the advocacy effort. “This change is a step toward recognition and better care.”
What’s Next for Patients and Providers?
The new name is expected to be adopted gradually by medical institutions and public health agencies. Guidelines for diagnosis and treatment are also under review to align with the updated terminology. While the change does not alter the medical approach to the condition, it represents a broader shift toward patient-centered language in healthcare.
Health officials emphasized that the reclassification does not diminish the importance of addressing the condition’s physical and emotional impacts. “The focus remains on improving outcomes for patients, whether through lifestyle changes, medication, or support networks,” said a representative from a global health organization.
